GSK's Bone Cancer Drug Meets Primary Endpoint in Late-stage China Study

06:32 AM EDT, 07/28/2026 (MT Newswires) -- GSK's (GSK.L) licensor Hansoh Pharmaceutical Group outlined positive results from the late-stage study of its antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, in patients with progressed or relapsed osteosarcoma. The phase III Artemis-011 trial, conducted in China, met its primary endpoint of progression-free survival, according to a Tuesday filing by the British drugmaker. The drug candidate showed significant improvements in progression-free survival, compared with chemotherapy. No new safety issues were identified, and Hansoh will submit the results for regulatory approval in China.